Alireza Atri, MD, PhD

The director of the Banner Sun Health Research Institute talked about how the newly approved Alzheimer treatments have shown promise in slowing clinical decline, signaling a foundational shift toward disease-modifying therapies that target core biological processes. [WATCH TIME: 5 minutes]

The director of the Banner Sun Health Research Institute provided commentary on his presentation at CTAD 2023 examining the value of donanemab and its effect on specific Alzheimer-related assessments. [WATCH TIME: 10 minutes]

Drs Atri, Cohen, Sabbagh and McDade share their enthusiasm and optimism about the future outlook for Alzheimer’s disease.

Dr Eric McDade shares information on different types of prevention trials to manage Alzheimer’s disease.

Expert neurologists share information on drugs with different mechanisms of actions that are being evaluated in clinical trials for Alzheimer’s disease.

Drs McDade and Atri discuss differences and similarities between other ongoing anti-amyloid antibody trials in Alzheimer’s disease.

Drs Cohen, Atri, and Sabbagh share data on lecanemab, an anti-amyloid beta antibody, that was presented at CTAD 2022.

Dr Atri comments on observation of amyloid related imaging abnormalities (ARIA) seen with many Alzheimer’s disease treatments and shares his thoughts on management of ARIA.

Dr Atri discusses aducanumab, first FDA approved anti-amyloid-beta antibody for treatment of Alzheimer’s disease.

Drs McDade, Atri, Cohen, and Sabbagh discuss candidates drugs and various mechanisms of actions that are currently under evaluation for Alzheimer’s disease.

Dr Atri emphasizes importance of managing neuropsychiatric symptoms in patients with Alzheimer’s disease and drugs under development.

Dr Cohen shares current treatment options for Alzheimer’s disease and how she manages these patients in her practice.

Dr Atri discusses considerations and suggestions for caring for patients with Alzheimer’s disease.

Dr. Cohen shares factors that may have contributed to the high failure rate of Alzheimer’s disease clinical trials thus far.

Drs McDade and Cohen discuss ATN (amyloid, tau, neurodegeneration) classification and its use in clinical practice to manage Alzheimer’s disease.

Dr Cohen emphasizes the importance of engagement of primary care physicians in identification of Alzheimer’s disease symptoms and pathology.

Dr. Atri discusses his approach to diagnosis and Dr. McDade updates on the use of tau-PET for diagnosis of Alzheimer’s disease.

Dr Atri shares his excitement about ongoing research and the use of biomarkers and imaging for management Alzheimer’s disease.

Drs McDade and Sabbagh discuss heterogeneity in Alzheimer’s disease and structural polymorphism and genetic mosaicism seen in patients.

Drs Atri and Cohen discuss biomarkers for Alzheimer’s disease and the challenges in their use in routine practice.

Four Alzheimer’s disease expert discuss our current understanding of Alzheimer’s disease pathology and the presence of amyloid and tau pathologies in patients.

Alireza Atri, MD, PhD, describes the pathophysiology of Alzheimer’s disease (AD).

In recognition of World Alzheimer Day, experts in Alzheimer disease and dementia share insight from the latest Alzheimer Disease International's yearly World Alzheimer Report.